Early immune-suppressing treatment for VKH eye disease
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial studies giving immune-suppressing treatment early in Vogt-Koyanagi-Harada (VKH) disease to see if it improves outcomes. It may help people reduce ongoing eye inflammation if they qualify and can be followed for a longer time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute Vogt-Koyanagi-Harada (VKH) disease
- You are willing and able to work with the study team (be “collaborative”)
- You can agree to have at least 1 year of follow-up visits or check-ins
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies adalimumab to treat a rare, fast-onset eye inflammation called Vogt-Koyanagi-Harada disease. It may help people who can’t use strong steroid treatments or whose disease is not improving quickly with them.
This early-stage trial tests a new injectable treatment called KSVCBD for autoimmune diseases that haven't responded well to standard therapies. The study aims to learn if it is safe and effective for conditions like lupus, vasculitis, and scleroderma.
This trial tests a new drug called vimseltinib for people with active chronic graft versus host disease (cGVHD) that hasn't gotten better after at least two prior treatments. The goal is to see if vimseltinib can help control the condition.
This trial tests if tacrolimus eye drops can safely treat severe eye allergies (vernal keratoconjunctivitis) in children ages 5 to 15. It aims to reduce symptoms like itching, redness, and discomfort.
This trial tests a new treatment made from your own immune cells (called LB-DTK-CMV) for a type of CMV eye infection that is not getting better with standard antiviral drugs. The goal is to see if these cells can safely control the infection and improve your vision.
This early-stage trial tests a new injection called KSVCBD to treat neuromyelitis optica spectrum disorder (NMOSD), a rare disease where the immune system damages the optic nerve and spinal cord. The study will examine whether this treatment is safe and helps reduce relapses in patients with a specific antibody marker.
Hear when a new Vogt Koyanagi Harada Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.